Organization
Melbourne, Australia
17 abstracts
Abstract
TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.Org: University of Paris-Saclay, Peter MacCallum Cancer Centre, Melbourne, Australia, National Cancer Center Hospital East, Kashiwa, Japan, Vall d’Hebron University Hospital/VHIO, Barcelona, Spain,
Abstract
Association of tumor infiltrating lymphocyte quantity with survival in patients (pts) with metastatic breast cancer (MBC) receiving microtubule-targeting agents: Post hoc analysis CALGB 40502 (Alliance).Org: Columbus, OH, GZA-ZNA Hospitals, Joan and Sanford I Weill Medical College of Cornell University, Weill Cornell Medicine, New York, NY,
Abstract
DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC.Org: Gustave Roussy Cancer Center, Université Paris-Saclay, Villejuif, France, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN,
Abstract
The potential role of serial circulating tumor DNA (ctDNA) testing after upfront surgery to guide adjuvant chemotherapy for early stage pancreatic cancer: The AGITG DYNAMIC-Pancreas trial.Org: Northern Health, Peter MacCallum Cancer Centre, Melbourne, Australia, Walter and Eliza Hall Institute of Medical Research, University of Melbourne, Melbourne, VIC, Australia,
Abstract
Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (DEP CTX) in patients with advanced solid cancers in a phase 1/2 trial (P1/2).Org: King's College London, Imperial College, University College London Cancer Institute, University College London Hospital NHS Trust and Great Ormond Street Hospital, Kinghorn Cancer Centre,
Abstract
Phase II study of neoadjuvant ipilimumab and nivolumab in combination with paclitaxel following anthracycline-based chemotherapy in patients with treatment resistant stage III triple negative breast cancer (TNBC): BCT1702—Survival results.Org: Peter MacCallum Cancer Centre, Melbourne, Australia, Breast Cancer Trials - Australia and New Zealand, NHMRC Clinical Trials Centre, Monash Health, Bentleigh East, VIC, Australia, Macarthur Cancer Therapy Center,
Abstract
Molecular tumor profiling and therapy selection in advanced gynecological cancers: A retrospective cohort analysis from the Australian Molecular Screening and Therapeutics (MoST) Program.Org: Austin Health and Peter MacCallum Cancer Centre, Melbourne, Australia, Garvan Institute of Medical Research, Sydney, Australia, The Kinghorn Cancer Centre,
Abstract
Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Safety analyses from the randomized, placebo (PBO)-controlled, phase 3 TALAPRO-2 study.Org: Peter MacCallum Cancer Centre, Melbourne, Australia, Melbourne, Australia, Australian Catholic University, Institut Gustave Roussy, University of Paris-Saclay,
Abstract
Updated efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (fp) non-small cell lung cancer (NSCLC).Org: Yonsei University College of Medicine, Seoul, Korea, Republic of (South), Taipei Medical University Hospital, Taipei City, Taiwan, City of Hope Comprehensive Cancer Center,
Abstract
The effect of adding a selective FAK inhibitor AMP945 to FOLFIRINOX in a model of pancreatic cancer.Org: Amplia Therapeutics, Melbourne, Australia, Australian Catholic University, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia,
Abstract
Long-term clinical and psychosocial outcomes of surveillance in Li Fraumeni syndrome.Org: Garvan Institute of Medical Research, Darlinghurst, NSW, Australia, Australian Catholic University, Sydney, NSW, Australia, Peter MacCallum Cancer Centre, Melbourne, Australia,
Abstract
An electrochemical molecular assay for the detection of cancer-associated Thomsen-Friedenreich glycans.Org: Swinburne University of Technology, Melbourne, Australia, Australian Catholic University, Universal Biosensors, Vicore Pharma,
Abstract
CHARLI: A phase Ib/II trial of ipilimumab-nivolumab-denosumab or nivolumab-denosumab in patients with unresectable stage III and IV melanoma.Org: Peter MacCallum Cancer Centre, Melbourne, Australia, Sir Charles Gairdner Hospital, Harry Perkins Institute for Medical Research, University of Western Australia & Linear Clinical Research, Melbourne, Australia,
Abstract
Real-world experience of tebentafusp for uveal melanoma via an Australian access program.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Peter MacCallum Cancer Centre, Melbourne, Australia, Melbourne, Australia, The Kinghorn Cancer Centre, Darlinghurst, Australia,
Abstract
A multicentre randomised controlled trial of zoledronic acid for osteoarthritis of the knee with bone marrow lesionsOrg: Menzies Institute for Medical Research, University of Tasmania, Hobart W. Harris, The Queen Elizabeth Hospital Kings Lynn NHS Trust, Woodville,
Abstract
Association between sledai-2k domains and organ damage accrualOrg: Monash University School of Public Health and Preventive Medicine, Melbourne, Australia, Australia Information Technology Faculty of Medicine Nursing and Health Sciences, Australian National University, Canberra, Australia,
Abstract
A PILOT STUDY USING A GENERIC, INDIRECT UTILITY MEASURE, THE SF-6D IN RHEUMATOID ARTHRITISOrg: Rheumatology, Austin Health, Psychiatry Department, Basurto University Hospital, Bilbao, United Kingdom, Royal Melbourne Hospital, Melbourne, Australia,